gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
Company profile
Ticker
GRTS
Exchange
Website
CEO
Andrew Allen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Gritstone Oncology, Inc.
SEC CIK
GRTS stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
10 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
9 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Departure of Directors or Certain Officers
29 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
1 Apr 24
Latest ownership filings
4
Andrew R Allen
17 May 24
4
Erin Jones
17 May 24
4
Karin Jooss
17 May 24
4
Matthew Hawryluk
17 May 24
4
Vassiliki Economides
17 May 24
4
James Cho
17 May 24
4
Stephen W Webster
30 Apr 24
3
Stephen W Webster
30 Apr 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 36.07 mm | 36.07 mm | 36.07 mm | 36.07 mm | 36.07 mm | 36.07 mm |
Cash burn (monthly) | 4.36 mm | 3.40 mm | 12.87 mm | 11.76 mm | 10.36 mm | 11.04 mm |
Cash used (since last report) | 33.20 mm | 25.94 mm | 98.05 mm | 89.57 mm | 78.95 mm | 84.14 mm |
Cash remaining | 2.88 mm | 10.13 mm | -61.98 mm | -53.50 mm | -42.88 mm | -48.07 mm |
Runway (months of cash) | 0.7 | 3.0 | -4.8 | -4.6 | -4.1 | -4.4 |
Institutional ownership, Q4 2023
7.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 1 |
Closed positions | 83 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 247.13 mm |
Total shares | 8.21 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Frazier Life Sciences Public Fund | 4.13 mm | $0.00 |
Versant Venture Capital V | 2.90 mm | $0.00 |
Frazier Healthcare VII | 1.03 mm | $21.20 mm |
Twin Peaks Wealth Advisors | 40.31 k | $82.24 mm |
SG Americas Securities | 39.09 k | $80.00 k |
SkyOak Wealt | 36.64 k | $74.75 mm |
Raymond James Financial Services Advisors | 22.07 k | $45.03 mm |
Diversified Trust | 11.49 k | $23.45 mm |
Allworth Financial | 100.00 | $204.00 k |
Nisa Investment Advisors | 94.00 | $192.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 24 | Matthew Hawryluk | Common Stock | Sell | Dispose S | No | No | 0.7483 | 9,259 | 6.93 k | 313,931 |
16 May 24 | Vassiliki Economides | Common Stock | Sell | Dispose S | No | No | 0.7483 | 13,749 | 10.29 k | 262,437 |
16 May 24 | Jooss Karin | Common Stock | Sell | Dispose S | No | No | 0.7483 | 13,749 | 10.29 k | 683,526 |
16 May 24 | Erin Jones | Common Stock | Sell | Dispose S | No | No | 0.7483 | 13,749 | 10.29 k | 359,293 |
16 May 24 | Allen Andrew R | Common Stock | Sell | Dispose S | No | No | 0.7483 | 24,263 | 18.16 k | 985,360 |
15 May 24 | Matthew Hawryluk | Common Stock | Grant | Acquire A | No | No | 0 | 19,149 | 0.00 | 323,190 |
15 May 24 | Matthew Hawryluk | Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 180,000 | 135.00 k | 180,000 |
15 May 24 | Vassiliki Economides | Common Stock | Grant | Acquire A | No | No | 0 | 27,128 | 0.00 | 276,186 |
15 May 24 | Vassiliki Economides | Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 215,000 | 161.25 k | 215,000 |
15 May 24 | Jooss Karin | Common Stock | Grant | Acquire A | No | No | 0 | 27,128 | 0.00 | 697,275 |
News
Beyond The Numbers: 4 Analysts Discuss Gritstone Bio Stock
13 May 24
HC Wainwright & Co. Maintains Buy on Gritstone Bio, Lowers Price Target to $4
13 May 24
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
10 May 24
12 Health Care Stocks Moving In Friday's Intraday Session
10 May 24
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
10 May 24
Press releases
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
9 May 24
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
29 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
24 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
20 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
16 Apr 24